Positive topline results reported in run-in cohort of reproxalap phase 3 trial
Reproxalap demonstrated statistically significant improvements in dry eye symptoms, redness and Schirmer’s test results compared with vehicle in a run-in cohort of the phase 3 TRANQUILITY clinical trial, Aldeyra Therapeutics announced.
